Lead: An anonymous sperm donor whose sperm carried a harmful mutation in the TP53 gene has been linked to at least 197 children born across 14 European countries over about 17 years. The mutation, associated with Li‑Fraumeni syndrome, can give carriers an up to 90% lifetime risk of cancer and already appears in multiple affected families, including some children who have died. Danish supplier European Sperm Bank has blocked the donor after the discovery; authorities in affected countries are notifying families and investigating how distribution and limits were handled.
Key takeaways
- At least 197 children were conceived using the donor’s sperm, distributed to fertility clinics in 14 countries over roughly 17 years.
- Up to 20% of the donor’s sperm carried a TP53 mutation that, when inherited in all cells, causes Li‑Fraumeni syndrome with up to a 90% cancer risk.
- Doctors initially reported 23 children with the variant among 67 known births; 10 of those had been diagnosed with cancer at that point.
- The donor passed standard screening and is healthy; the mutation arose as a mosaic change before his birth and was not detectable by routine tests.
- The European Sperm Bank acknowledged breaches of national usage limits in some countries and has blocked the donor after learning of the problem.
- Denmark informed the UK’s HFEA that a very small number of British patients travelled to Denmark and were using the donor’s sperm; those patients have been contacted.
- National donor limits vary: Belgium allows six families per donor but recorded 38 women producing 53 children from this donor; the UK limit is 10 families.
Background
The sperm was first donated in 2005 by a student who satisfied the usual medical and infection screening and remained clinically well. Over the following 17 years his samples were sold by the European Sperm Bank and used at least 67 fertility clinics in 14 countries, raising cross‑border traceability and oversight questions. The genetic problem is a mosaic mutation affecting TP53, a key tumour suppressor; only a fraction of the donor’s sperm carried the defect, but any child conceived from a mutated sperm would inherit the change in every cell.
Li‑Fraumeni syndrome, caused by germline TP53 mutations, is rare but severe: carriers face very high lifetime cancer risk, with many tumours arising in childhood and others, such as breast cancer, occurring in adulthood. Routine donor screening typically focuses on transmissible infections and a subset of heritable conditions; mosaic post‑zygotic or early embryonic mutations in donors are difficult to detect without whole‑genome or targeted deep sequencing of multiple tissues. The case exposed gaps in how international banks distribute gametes and how national usage limits are enforced.
Main event
Clinicians began to notice clusters of children with the same TP53 variant and alerted colleagues at the European Society of Human Genetics and in specialist centres. Initial clinical reports identified dozens of children with the variant and multiple early cancers; subsequent Freedom of Information requests and interviews expanded the known number to at least 197 children conceived with the donor’s sperm. The precise number of mutation carriers among those births remains uncertain because not all children have been tested or reported.
The European Sperm Bank said it had blocked the donor once concerns surfaced and expressed sympathy to affected families, while also stating that the mutation was not detectable by standard proactive screens. National regulators in Denmark, Belgium and other countries are reviewing whether local limits on donor use were exceeded and investigating clinic practices. In Belgium, for example, a single donor was used far beyond the legal limit: 38 women produced 53 children from this donor despite a six‑family cap.
Health authorities have been contacting patients who received treatment with the donor’s sperm. The UK’s HFEA confirmed that a very small number of British patients had travelled to Denmark to be treated with the donor’s sperm and that those patients had been informed by the Danish clinic. Clinicians are offering genetic testing and cancer surveillance to identified carriers and their families, with recommendations that may include regular MRI surveillance and, in some cases, prophylactic surgery for adults at particularly high risk.
Analysis & implications
This case illustrates two intersecting problems: the biological limits of donor screening and the regulatory challenges of increasingly globalised sperm supply. Standard screening filters out infections and some heritable conditions, but it cannot guarantee detection of all mosaic or de novo mutations present in a subset of germ cells. That scientific fact means some residual risk will always remain unless whole‑donor deep genetic sequencing becomes routine, which brings cost, logistics and ethical trade‑offs.
From a regulatory perspective, cross‑border sales amplify risk because a single donor in a large international bank can be used by dozens or hundreds of families in multiple jurisdictions. National caps on donor offspring aim to limit genetic relatedness and safeguard offspring wellbeing, but they are only effective if enforced and if banks respect country‑level restrictions. In this case, documented breaches in some countries suggest enforcement gaps and the need for clearer international standards or improved traceability.
The human consequences are acute: families face a prospect of lifelong intensive surveillance for cancer, and some affected children have already developed multiple malignancies or died. The psychosocial burden includes anxiety, difficult decisions about preventive healthcare, and complex feelings about the use of donor gametes. Policy responses must therefore weigh the medical benefits of expanded genetic screening, the privacy and consent implications of reporting additional findings, and the social harms of concentrating many genetically related children from single donors.
Comparison & data
| Metric | Reported value |
|---|---|
| Known children conceived from donor | At least 197 |
| Clinics supplied | 67 clinics in 14 countries |
| Initial clinical report | 23 children tested; 10 with cancer |
| Fraction of donor sperm with mutation | Up to 20% |
| Belgian families from donor | 38 women produced 53 children (limit 6) |
The table summarises the confirmed counts to date; numbers may increase as more clinics and families are traced and tested. National limits vary (Belgium 6 families, UK 10 families); professional societies have proposed alternative caps such as 50 families to address psychosocial concerns rather than genetic risk.
Reactions & quotes
Clinicians and patient advocates have expressed shock and concern while calling for swift patient notification and review of procedures. Geneticists emphasise the serious clinical implications for carriers and the need for long‑term follow‑up.
It is a dreadful diagnosis and a lifelong burden for families who inherit this risk.
Prof Clare Turnbull, Institute of Cancer Research (cancer geneticist)
You can’t screen for everything; large international banks and cross‑border sales complicate oversight.
Prof Allan Pacey, University of Manchester (reproductive biologist)
More must be done to reduce the number of families born globally from the same donors to protect children’s wellbeing.
Sarah Norcross, Progress Educational Trust (charity director)
Unconfirmed
- Exact number of children who inherited the TP53 mutation remains unknown because not all offspring have been tested or reported.
- Comprehensive data from all countries where the donor’s samples were used have not yet been obtained; the 197 figure may rise as further records are released.
- Full details of how national usage limits were exceeded in specific clinics are still under regulatory review and not yet publicly confirmed in every jurisdiction.
Bottom line
The case shows a rare but severe consequence of gaps in genetic detectability and international sperm distribution: a single donor’s mosaic mutation has potentially exposed many families across Europe to a high cancer risk in their children. Immediate priorities are identifying affected children, offering genetic testing and clinical surveillance, and supporting families facing difficult choices about care and prevention.
Longer term, regulators, professional bodies and banks must strengthen traceability, harmonise or better enforce usage limits, and consider whether expanded genetic testing or different consent frameworks are needed. Any policy change should balance the medical benefits, the privacy of donors and recipients, and the broader social impacts of concentrating genetic relatedness through international gamete markets.
Sources
- BBC News (media report summarising investigation by public broadcasters)
- European Sperm Bank (official donor bank statement)
- Human Fertilisation & Embryology Authority (UK regulator, official)
- European Society of Human Reproduction and Embryology (professional society)
- Rouen University Hospital (clinical centre reporting cases)